Swipe to discover more

• bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

  bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.

  Read the press release
  

• A Balancing Act: Fighting Sepsis and Antimicrobial Resistance at the Same Time

  Studies show that the rapid administration of antibiotics has been generally associated with a decrease in deaths among hospitalized patients with sepsis. However, the need to quickly administer effective therapy can lead to clinicians turning to broad-spectrum antibiotics, which can exacerbate antimicrobial resistance (AMR). Because AMR is a major healthcare concern—including for patients with sepsis—improving the alignment between sepsis protocols and antimicrobial stewardship (AMS) guidelines is important for patient care.

  Read the blog post
  

• bioMérieux and Moderna Collaborate to Advance individualized Cancer Therapies

  bioMérieux has a long history of collaboration with Moderna, a biotechnology company that gained worldwide recognition during the COVID-19 pandemic for its rapid development of a mRNA-based vaccine. Today, this collaboration is helping accelerate the development of individualized cancer treatments.

  Read the news